Teva receives FDA approval for colon cancer generic
JERUSALEM The Food and Drug Administration has approved a generic version of a colon cancer treatment.
Teva Pharmaceutical Industries announced last week the approval and launch of oxaliplatin, an injectable drug, in the 50 mg per 10 milliliter and 100 mg per 20 milliliter strengths. The drug is a generic version of Debiopharm’s and Sanofi-Aventis’ Eloxatin and is approved as an adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.
In June, the U.S. District Court for the District of New Jersey ruled in Teva’s favor, finding that Teva did not infringe U.S. Patent No. 5,338,874, Debiopharm’s patent on Eloxatin. Sanofi and Debiopharm have appealed the decision, and Sanofi has sued the FDA seeking to rescind all approvals of generic oxaliplatin pending resolution of the appeal.
Eloxatin had sales of $1.3 billion in the United States last year, according to IMS Health data.
Report: PhRMA backs healthcare reform
NEW YORK Most of the groups supporting President Obama’s healthcare reform plan have been patient advocates such as AARP, but the effort recently got some help from a different and traditionally conservative source: the drug industry.
Advertising Age reported Thursday that the Pharmaceutical Research and Manufacturers of America, the largest trade group for the brand drug industry, will set aside $150 million for an advertising campaign in support of healthcare reform, including TV ads in 12 key states, as well as radio and print ads. An executive from PhRMA told the advertising industry trade magazine that the ads would focus on ensuring that everyone has access to health insurance, including affordable co-payments and no denials based on pre-existing conditions.
The healthcare reform debate has turned contentious in recent weeks, with townhall meetings across the country disrupted by loud protests from opponents of reform who think it will harm healthcare more than it helps and will damage the economy.
QuikTrip opens second clinic for employees
KANSAS CITY, Mo. Convenience store operator QuikTrip Corp. has opened its second worksite health clinic for its employees in the Kansas City area, according to a local news report.
QuikTrip, which operates more than 500 convenience stores, opened its first worksite clinic two years ago at its headquarters in Tulsa, Okla.
The new 1,400-sq.-ft. Belton clinic is administered by Care ATC, a national provider of on-site medical clinics, and provides free services to the nearly 800 QuikTrip employees and their dependents in that area, the report stated.
The facility provides the same services as a primary care physician’s office and is staffed by a board-certified physician and others who are employees of Care ATC.
As previously reported by Drug Store News, worksite clinics are on the rise as employers increasingly look for ways to lower healthcare costs and bolster employee productivity.
It is estimated by Fuld & Company that there are some 1,200 firms currently operating on-site clinics, which, taking into account their multiple campuses and multiple clinics, results in an estimated 2,200 on-site clinics. That number could reach 7,000 by 2015.